Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail
by Zacks Equity Research
Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business
by Zacks Equity Research
According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.
Lantheus Holdings, Inc. (LNTH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.
4 Stocks to Watch Amid Recovering Medical Products Industry
by Indrajit Bandyopadhyay
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.
3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock
by Zacks Equity Research
Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Haemonetics (HAE) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
by Zacks Equity Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Gains on Procedure Recovery Amid Cost Woes
by Zacks Equity Research
A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Here's Why Investors Should Retain Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Product Stocks Set to Beat on Earnings This Season
by Trina Mukherjee
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
Clover Health (CLOV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.
Viemed Healthcare, Inc. (VMD) Lags Q1 Earnings Estimates
by Zacks Equity Research
Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -33.33% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.